NYU Langone Health, NYU Langone Orthopedic Hospital, New York, New York, USA.
Am J Sports Med. 2022 Jan;50(1):162-169. doi: 10.1177/03635465211057117. Epub 2021 Nov 17.
Autologous osteochondral transplantation (AOT) using a cylindrical graft in the treatment of osteochondral lesions of the talus (OLTs) is typically indicated for patients with larger lesions. However, with lesions that are irregular in shape, the AOT graft may not completely replace the lesion. For these lesions, we utilize extracellular matrix cartilage allograft (EMCA) augmentation in AOT to act as a physiologic grout at the host-graft interface.
To determine if the combination of EMCA with concentrated bone marrow aspirate (CBMA) would improve integration of the host-graft interface and subsequently reduce postoperative cyst formation after AOT. It was also hypothesized that EMCA in conjunction with CBMA would demonstrate improved MOCART (magnetic resonance observation of cartilage repair tissue) scores and functional outcome scores at a minimum 2 years after surgery.
Cohort study; Level of evidence, 3.
A retrospective analysis was performed comparing patients treated with AOT/CBMA alone and AOT with CBMA/EMCA. Clinical outcomes were evaluated with the Foot and Ankle Outcome Score. Magnetic resonance imaging appearance was evaluated with the use of the MOCART (magnetic resonance observation of cartilage repair tissue) score. Cyst formation was also evaluated on postoperative magnetic resonance imaging.
A total of 26 patients were included in the AOT + CBMA/EMCA group (10 male, 16 female), and 34 patients were included in the AOT/CBMA group (17 male, 17 female). The mean Foot and Ankle Outcome Score significantly improved in both groups ( < .001) across all subscales (symptoms, pain, activities of daily living, sports activities, and quality of life), but there was no significant difference between groups at final follow-up. There was no significant difference in mean MOCART scores between the groups ( = .118). In the AOT/CBMA group, 3 patients (8.8%) complained of knee pain, and 1 (2.9%) required additional surgery (hardware removal). In the AOT + CBMA/EMCA group, 2 patients (7.7%) complained of knee pain, and 6 patients (23%) required additional surgery (3 hardware removals and 3 arthroscopic debridements of scar tissue in the ankle).
We found that while EMCA with CBMA has benefit in regeneration and repair of OLT treated with bone marrow stimulation, there appears to be little benefit of EMCA over CBMA alone as a physiologic grout at the graft-host interface in OLT treated with AOT.
自体骨软骨移植(AOT)使用圆柱移植物治疗距骨骨软骨病变(OLTs),通常适用于较大病变的患者。然而,对于形状不规则的病变,AOT 移植物可能无法完全替代病变。对于这些病变,我们在 AOT 中使用细胞外基质软骨同种异体移植物(EMCA)增强来充当宿主-移植物界面的生理性灌浆料。
确定 EMCA 与浓缩骨髓抽吸物(CBMA)联合使用是否会改善宿主-移植物界面的整合,并随后减少 AOT 后术后囊肿的形成。还假设 EMCA 与 CBMA 联合使用将在手术后至少 2 年显示出改善的 MOCART(磁共振软骨修复组织观察)评分和功能结果评分。
队列研究;证据水平,3 级。
对单独接受 AOT/CBMA 治疗和接受 AOT 联合 CBMA/EMCA 治疗的患者进行回顾性分析。临床结果采用足踝结果评分(Foot and Ankle Outcome Score)进行评估。磁共振成像外观采用 MOCART(磁共振软骨修复组织观察)评分进行评估。术后磁共振成像还评估了囊肿形成情况。
共有 26 例患者纳入 AOT+CBMA/EMCA 组(男性 10 例,女性 16 例),34 例患者纳入 AOT/CBMA 组(男性 17 例,女性 17 例)。两组所有亚组(症状、疼痛、日常生活活动、运动活动和生活质量)的足踝结果评分均显著改善(均<0.001),但最终随访时两组之间无显著差异。两组之间的平均 MOCART 评分无显著差异(=0.118)。在 AOT/CBMA 组中,3 例(8.8%)患者诉膝关节疼痛,1 例(2.9%)需要额外手术(取出内固定物)。在 AOT+CBMA/EMCA 组中,2 例(7.7%)患者诉膝关节疼痛,6 例(23%)需要额外手术(3 例取出内固定物和 3 例踝关节镜下清除疤痕组织)。
我们发现,虽然 EMCA 联合 CBMA 有益于骨髓刺激治疗的 OLT 的再生和修复,但在 AOT 治疗的 OLT 中,EMCA 作为宿主-移植物界面的生理性灌浆料,其益处似乎不如 CBMA 单独使用。